New AmsterdamPharma
New AmsterdamPharma raises $453M Series at $2B valuation
Quick Facts
New AmsterdamPharma: Series Funding Round
New AmsterdamPharma has successfully raised $453M in Series funding, reaching a valuation of $2B.
Company Overview
Developing novel cholesterol treatment drug for cardiovascular disease
Funding Details
The Series round was led by RA Capital, with participation from RTW Investments.
Company Information
- Headquarters: Amsterdam, Netherlands
- Founded: 2019
- Employees: 120+
- Category: Biotech
Investment
New AmsterdamPharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital: Verified investor in Series
- RTW Investments: Verified investor in Series
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
